mosliciguat
mosliciguat: developed by 1 company · 1 clinical trial tracked.
mosliciguat evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect mosliciguat to ROIV; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could mosliciguat → ROIV affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Related indications
Pulmonary Hypertension associated with Interstitial Lung DiseaseCardiovascular DiseasesInterstitial Lung DiseaseLung DiseasesPulmonary HypertensionVascular Diseases
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Roivant Sciences Ltd. (ROIV) Pulmonary Hypertension associated with Interstitial Lung Dis… | Phase 2 |
Clinical Trials (1)
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Primary endpoint: Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)
InterventionalRandomizedquadruple135 targetStarted 2024-10Completion 2028-0118 sites · United StatesPulmovant, Inc.
Frequently asked questions
Who is developing mosliciguat?
mosliciguat is being developed by Roivant Sciences Ltd..
How many clinical trials involve mosliciguat?
BioSniper tracks 1 clinical trial involving mosliciguat.